IRVINE, Calif., June 28 /PRNewswire-FirstCall/ -- Masimo (Nasdaq: MASI), the inventor of Masimo Rainbow Pulse CO-Oximetryâ„¢, Masimo Rainbow Acoustic Monitoringâ„¢, and Masimo SET® Measure-Through Motion and Low Perfusion pulse oximetry, today announced FDA 510(k) clearance for the Pronto-7™—a new handheld device designed for quick and easy noninvasive hemoglobin (SpHb®) spot-check testing, along with SpO2, pulse rate, and perfusion index, in virtually any environment. (Photo: http://photos.prnewswire.com/prnh/20100628/LA27359) (Photo: http://www.newscom.com/cgi-bin/prnh/20100628/LA27359) Masimo Founder and CEO, Joe Kiani, stated: "We are happy that in addition to the CE Marking we now have FDA clearance for Pronto-7, allowing U.S.
Mimotopes Awarded Major Peptide Supply Contract by the Queensland Institute of Medical Research in the Search for an Effective Malaria Vaccine
Mimotopes' PepSets™ to be used to identify novel proteins from the malaria parasite for next generation vaccine development
Mimotopes Awarded a Major Peptide Library Supply Agreement by La Jolla Institute for their Studies Screening Dengue and Tuberculosis Pathogens
Mimotopes PepSets to be used by the La Jolla Institute to identify regions of the dengue virus and Mycobacterium tuberculosis that can be targeted by new vaccines
